AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Galapagos to present at 38th Annual J.P. Morgan Healthcare Conference

January 9, 2020 GMT

Mechelen, Belgium; 9 January 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 38th Annual J.P. Morgan Healthcare Conference on January 14-16, 2020.

Bart Filius, COO & CFO, will present on Thursday, January 16 at 19:30 CET (10:30 a.m. Pacific time). The presentation will be live audio webcast and can be accessed via the following link: https://jpmorgan.metameetings.net/events/hc20/sessions/29715-galapagos-nv/webcast. A replay of the webcast will be available for 90 days on the Galapagos’ website at www.glpg.com.

About GalapagosGalapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:Elizabeth GoodwinVP Investor Relations +1 781 460 1784

Sofie Van GijselDirector Investor Relations+32 485 19 14 15ir@glpg.com

Media:Carmen VroonenSenior Director Communications & Public Affairs+32 473 824 874

Evelyn FoxDirector Communications +31 6 53 591 999

communications@glpg.com

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Attachment

-- PDF version